Equities

Viracta Therapeutics Inc

Viracta Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.6738
  • Today's Change0.032 / 5.00%
  • Shares traded128.40k
  • 1 Year change-56.53%
  • Beta0.7565
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.

  • Revenue in USD (TTM)0.00
  • Net income in USD-47.99m
  • Incorporated1998
  • Employees40.00
  • Location
    Viracta Therapeutics Inc2533 S COAST HWY 101, SUITE 210CARDIFF BY THE SEA 92007United StatesUSA
  • Phone+1 (858) 400-8470
  • Fax+1 (650) 266-3501
  • Websitehttps://www.viracta.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Aptorum Group Ltd431.38k-2.82m24.73m3.00--0.9427--57.33-0.9126-0.91260.09544.800.020830.363.88143,793.30-20.92-40.45-19.62-42.362.45-4.04-1,006.30-1,233.681.18--0.1694---66.712.3871.18---78.15--
Equillium Inc37.89m-12.13m25.14m44.00--1.19--0.6633-0.3476-0.34761.080.59830.6568--8.95861,227.30-21.02-46.81-39.66-57.36-----32.01-328.35----0.00--128.97--78.64--7.48--
Aspira Women's Health Inc8.99m-14.74m25.40m64.00------2.82-1.33-1.330.8698-0.11040.963713.765.83140,484.40-158.00-110.58-395.41-151.8858.8445.23-163.95-334.081.11--3.10--11.8524.5644.15---26.65--
AIM ImmunoTech Inc193.00k-31.12m25.65m26.00--5.45--132.92-0.637-0.6370.0040.0960.0072--0.21897,423.08-116.00-45.64-148.40-48.3574.09-231.75-16,123.32-11,695.01----0.3478--43.26-11.26-48.94--35.73--
Oncternal Therapeutics Inc1.15m-36.38m26.00m27.00--1.13--22.59-12.35-12.350.39077.750.0263----42,629.63-83.23-49.40-95.97-54.51-----3,160.73-1,342.98----0.00---47.32--10.62------
Correlate Energy Corp7.95m-13.85m26.08m19.00------3.28-0.3747-0.37470.2157-0.1452.76--26.10418,160.50-481.76-315.47----17.9815.42-174.38-201.03---1.07----122.2046.12-78.54------
Trinity Biotech plc (ADR)56.71m-33.88m26.31m380.00------0.464-4.42-2.817.41-14.960.6251.693.67149,229.00-37.34-20.30-47.55-29.5434.2139.92-59.75-29.861.03-1.961.36---9.10-10.1515.41---31.08--
Shineco Inc5.62m-14.34m26.36m87.00--0.7325--4.69-3.98-2.321.365.580.06640.481.4564,633.68-19.79-12.77-38.28-16.8412.7725.88-298.09-102.060.4842-8.140.3908-----58.35-33.86------
Qilian International Holding Group Ltd46.47m-7.78m26.44m298.00--0.618--0.569-0.2176-0.21761.301.200.80276.4533.30155,944.60-14.032.71-16.843.863.7711.66-17.482.724.43-0.48120.010726.11-28.35-1.60-822.64--12.86--
Viracta Therapeutics Inc0.00-47.99m26.46m40.00--4.70-----1.24-1.240.000.28210.00----0.00-75.51-86.35-112.64-106.38-------11,853.94---84.180.6277-------3.78------
Spruce Biosciences Inc10.13m-46.75m26.74m22.00--0.4013--2.64-1.15-1.150.24831.620.0894----349,206.90-41.26-41.24-50.47-46.49-----461.67-1,774.39---114.540.0423-------3.77------
Biora Therapeutics Inc544.00k-111.08m26.82m58.00------49.30-7.13-7.120.0267-3.290.0143--0.65949,379.31-291.43-122.84-482,965.20-369.01-----20,419.48-415.10---------98.69-87.44-154.63---53.68--
Alterola Biotech Inc0.00-2.88m27.31m1.00---------0.0027-0.00270.00-0.0010.00----0.00-47.24---63.88----------0.0019----------73.07------
Janone Inc0.00-18.58m27.54m5.00---------3.66-3.950.001.010.00----0.00-69.38-23.12-88.46-62.22--23.38---30.14----0.1264-------313.15------
IGC Pharma Inc1.22m-14.15m27.77m61.00--2.94--22.84-0.2479-0.24790.02170.1420.07760.20847.0919,934.43-90.30-33.35-100.90-35.8451.408.74-1,163.24-410.260.8564--0.0153--129.47-16.1123.38--25.28--
BioVie Inc0.00-37.18m28.07m18.00--1.48-----0.9626-0.96260.000.31040.00----0.00-94.32-456.35-149.75-1,810.88------------0.2969-------92.67------
Data as of Jun 14 2024. Currency figures normalised to Viracta Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

21.50%Per cent of shares held by top holders
HolderShares% Held
BVF Partners LPas of 31 Mar 20243.61m9.20%
Citadel Advisors LLCas of 31 Mar 20241.52m3.87%
The Vanguard Group, Inc.as of 31 Mar 20241.15m2.94%
Laurion Capital Management LPas of 31 Mar 2024420.43k1.07%
MAI Capital Management LLCas of 31 Mar 2024364.10k0.93%
BlackRock Fund Advisorsas of 31 Mar 2024298.44k0.76%
Aisling Capital Management LPas of 31 Mar 2024288.57k0.74%
Medical Strategy GmbHas of 30 Nov 2023278.12k0.71%
Geode Capital Management LLCas of 31 Mar 2024252.70k0.64%
Apo Asset Management GmbHas of 30 Sep 2023252.15k0.64%
More ▼
Data from 29 Feb 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.